Skip to content

Comparison of Resting Heart and Respiratory Rate Measurements Acquired by Contactless Radar Sensors, Electrocardiography, and Capnography

Comparison of Resting Heart and Respiratory Rate Measurements Acquired by Contactless Radar Sensors, Electrocardiography, and Capnography

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04935190
Acronym
Vitalpercept
Enrollment
100
Registered
2021-06-22
Start date
2021-06-15
Completion date
2021-10-30
Last updated
2021-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vital Signs

Brief summary

1. Determine agreement (accuracy) of resting heart rate measured by Vitalpercept when compared to an FDA-cleared electrocardiograph (ECG) device, LifeSignals Wireless Biosensor. 2. Determine agreement (accuracy) of resting respiratory rate measured by Vitalpercept when compared to an FDA-cleared capnographer, Capnostream 20.

Interventions

DIAGNOSTIC_TESTVitalpercept

Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography

Sponsors

DawnLight
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Male or female subjects ≥ 21 years of age at the time of signing the informed consent. 2. Subjects willing to sign the informed consent and capable of committing to the duration of the study. 3. Subjects with the ability to lie flat, lie on left side, lie on right side, and sit in a chair. 4. Subjects who are able to breathe through their nose for the capnography assessment. 5. Subjects that have a diagnosis of a cardiac, pulmonary, or cardio-pulmonary condition (e.g., Congestive Heart Failure, COPD, Asthma) will be assigned to Group 1. 6. Subjects who are not known to have a cardiac, pulmonary, or cardio-pulmonary condition will be assigned to Group 2.

Exclusion criteria

1. Subjects who are prone to excessive coughing and excessive movement 2. Subjects who have a condition that involves uncontrollable movement of the body such as Parkinson's Disease or Essential Tremor. 3. Subjects with a history of allergy to adhesive, latex or Nuprep.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Adverse eventsDuring Data collection-Expected time=45-60 minutesSafety
Measurement of Heart RateDuring Data collection-Expected time=45-60 minutesEffectiveness
Measurement of Respiratory RateDuring Data collection-Expected time=45-60 minutesEffectiveness

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026